A detailed history of Legal & General Group PLC transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 43,582 shares of VERA stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,582
Previous 43,582 -0.0%
Holding current value
$1.8 Million
Previous $1.93 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$34.09 - $46.71 $4,193 - $5,745
123 Added 0.28%
43,582 $1.93 Million
Q2 2024

Aug 14, 2024

BUY
$33.72 - $48.82 $193,788 - $280,568
5,747 Added 15.24%
43,459 $1.57 Million
Q1 2024

May 14, 2024

BUY
$14.91 - $49.14 $189,685 - $625,159
12,722 Added 50.91%
37,712 $1.63 Million
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $293,023 - $419,765
21,373 Added 590.9%
24,990 $342,000
Q2 2023

Aug 14, 2023

BUY
$6.11 - $17.83 $6,342 - $18,507
1,038 Added 40.25%
3,617 $58,000
Q1 2023

May 15, 2023

SELL
$5.41 - $18.3 $17,999 - $60,884
-3,327 Reduced 56.33%
2,579 $20,000
Q4 2022

Feb 14, 2023

BUY
$15.74 - $22.19 $8,184 - $11,538
520 Added 9.65%
5,906 $114,000
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $6,475 - $10,887
488 Added 9.96%
5,386 $114,000
Q2 2022

Aug 22, 2022

BUY
$12.82 - $23.4 $46,036 - $84,029
3,591 Added 274.75%
4,898 $67,000
Q1 2022

May 16, 2022

BUY
$17.8 - $28.06 $6,657 - $10,494
374 Added 40.09%
1,307 $31,000
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $4,067 - $9,701
271 Added 40.94%
933 $25,000
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $9,076 - $20,257
662 New
662 $12,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.12B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.